Logo

GRCE

Grace Therapeutics, Inc.

GRCE

Grace Therapeutics, Inc. • NASDAQ
$3.18 ▼ -0.93% (-0.03)
Market Cap $44.95 M
52w High $4.97
52w Low $1.75
Dividend Yield 0%
P/E -6
Volume 23.84K
Outstanding Shares 14.13M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2026 $0 $2.529M ▼ $-938K ▲ 0% $-0.06 ▲ $-938K ▲
Q1-2026 $0 $3.09M ▼ $-3.362M ▼ 0% $-0.21 ▼ $-3.088M ▼
Q4-2025 $0 $3.181M ▼ $636K ▲ 0% $0.046 ▲ $-380K ▲
Q3-2025 $0 $3.704M ▼ $-4.155M ▼ 0% $-0.36 ▼ $-3.702M ▲
Q2-2025 $0 $4.831M $-3.432M 0% $-0.3 $-4.829M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2026 $16.862M ▼ $66.576M ▼ $3.758M ▼ $62.818M ▼
Q1-2026 $20.005M ▼ $69.805M ▼ $6.255M ▲ $63.55M ▼
Q4-2025 $22.133M ▲ $71.993M ▲ $5.383M ▼ $66.61M ▲
Q3-2025 $11.055M ▼ $61.224M ▼ $9.085M ▼ $52.139M ▼
Q2-2025 $15.17M $65.349M $9.215M $56.134M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2026 $-938K ▲ $-3.155M ▼ $0 $-769.846 ▲ $-3.143M ▼ $-3.155M ▼
Q1-2026 $-3.362M ▼ $-1.801M ▲ $0 $-327K ▼ $-2.128M ▼ $-1.801M ▲
Q4-2025 $636K ▲ $-2.954M ▲ $0 ▼ $14.032M ▲ $11.078M ▲ $-2.954M ▲
Q3-2025 $-4.155M ▼ $-4.115M ▲ $15K ▲ $0 $-4.1M ▲ $-4.115M ▲
Q2-2025 $-3.432M $-4.239M $0 $0 $-4.239M $-4.239M

Five-Year Company Overview

Income Statement

Income Statement Grace Therapeutics is still a pure research-stage company: it has essentially no product revenue yet and runs entirely on spending for development and overhead. Losses have been steady but relatively small in absolute terms, reflecting a lean cost structure rather than aggressive expansion. Earnings per share look very volatile, but much of that is driven by repeated reverse stock splits and capital structure changes, not sudden swings in the underlying business. Overall, this is a classic pre-commercial biotech profile: controlled but ongoing losses with no operating income until a drug is approved and launched.

Balance Sheet

Balance Sheet The balance sheet is small and simple. The company holds a modest amount of cash and total assets, carries no financial debt, and has positive but thin equity. This “clean but light” balance sheet means there is no heavy leverage risk, but also not much of a cushion if timelines slip or trials become more expensive. Multiple past reverse splits suggest a history of share price pressure and likely reliance on issuing new shares to fund operations. Financially, the company looks fragile but not overburdened by obligations.

Cash Flow

Cash Flow Cash flow mirrors the income statement: a steady stream of modest operating cash outflows tied to R&D and corporate costs, with no offsetting inflows from product sales yet. There is essentially no spending on large physical assets, so cash burn is almost entirely related to people, trials, and development work. This is manageable in size but ongoing, meaning that without a successful approval and commercial launch, the business will likely continue to depend on external financing to sustain its pipeline.

Competitive Edge

Competitive Edge Grace competes in a focused niche: reformulating known drugs for rare and orphan diseases. Its main defenses are regulatory and legal rather than sheer scale. Orphan Drug designations offer market exclusivity in specific conditions, and a sizable patent portfolio protects its delivery technologies and formulations. These create a meaningful moat in narrow indications. At the same time, the company is small, with limited commercial infrastructure, and operates in markets where specialist competitors, hospital buying patterns, and reimbursement decisions can heavily influence uptake. Success depends on turning technical and regulatory advantages into real-world adoption in a few highly specialized areas.

Innovation and R&D

Innovation and R&D The core innovation is not inventing brand‑new molecules, but improving how existing ones are delivered to the body. By using sprays and intravenous formulations of known drugs, Grace is trying to offer faster, more reliable, or more convenient treatment in serious and underserved diseases. This approach can lower scientific risk because the active ingredients are already understood, but it does not remove regulatory, clinical, or commercial risk. The pipeline is fairly concentrated: a late‑stage hospital product for brain hemorrhage, a spray for a rare genetic children’s disease, and a topical pain treatment. Execution on these few programs, especially the lead candidate under FDA review, will largely determine whether the R&D strategy pays off.

Summary

Grace Therapeutics is a classic late‑stage, pre‑revenue biotech: small, focused, and financially tight, with no current sales but a defined pipeline aimed at high‑need rare diseases. Its strengths lie in orphan drug status, a protective patent estate, and a lower‑risk scientific model built on reformulating known drugs, all of which could produce meaningful value if key approvals and launches go well. On the other hand, the company’s limited cash base, lack of revenue, repeated reverse splits, and dependence on a handful of assets highlight significant execution and funding risk. Future outcomes hinge on regulatory decisions, trial results, the ability to finance operations through to commercialization, and how effectively the company can convert its niche scientific edge into sustainable demand in real clinical practice.

NEWS

November 17, 2025 · 8:00 AM UTC

Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

Read more

November 13, 2025 · 8:00 AM UTC

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

Read more

November 11, 2025 · 8:30 AM UTC

Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting

Read more

October 23, 2025 · 8:00 AM UTC

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

Read more

September 22, 2025 · 8:00 AM UTC

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

Read more